Eversept Partners LP Sells 992,513 Shares of Teva Pharmaceutical Industries Limited (NYSE:TEVA)

Eversept Partners LP reduced its holdings in Teva Pharmaceutical Industries Limited (NYSE:TEVA - Free Report) by 30.7% in the fourth quarter, according to its most recent filing with the Securities & Exchange Commission. The institutional investor owned 2,242,125 shares of the company's stock after selling 992,513 shares during the period. Teva Pharmaceutical Industries makes up 4.4% of Eversept Partners LP's portfolio, making the stock its 6th largest holding. Eversept Partners LP owned approximately 0.20% of Teva Pharmaceutical Industries worth $49,416,000 as of its most recent SEC filing.

A number of other large investors have also recently made changes to their positions in the business. Stifel Financial Corp raised its holdings in Teva Pharmaceutical Industries by 54.0% during the 3rd quarter. Stifel Financial Corp now owns 66,391 shares of the company's stock valued at $1,196,000 after buying an additional 23,283 shares during the period. Barclays PLC increased its position in Teva Pharmaceutical Industries by 31.7% during the third quarter. Barclays PLC now owns 427,595 shares of the company's stock valued at $7,705,000 after acquiring an additional 102,848 shares during the last quarter. Sanctuary Advisors LLC raised its stake in shares of Teva Pharmaceutical Industries by 1.9% in the third quarter. Sanctuary Advisors LLC now owns 35,129 shares of the company's stock valued at $601,000 after acquiring an additional 664 shares during the period. Wilmington Savings Fund Society FSB bought a new stake in shares of Teva Pharmaceutical Industries in the 3rd quarter worth about $50,000. Finally, Franklin Resources Inc. boosted its stake in shares of Teva Pharmaceutical Industries by 141.7% during the 3rd quarter. Franklin Resources Inc. now owns 155,091 shares of the company's stock worth $2,674,000 after purchasing an additional 90,920 shares during the period. 54.05% of the stock is currently owned by institutional investors.

Analysts Set New Price Targets

Several brokerages have issued reports on TEVA. StockNews.com raised shares of Teva Pharmaceutical Industries from a "hold" rating to a "buy" rating in a research note on Wednesday. Barclays dropped their price objective on Teva Pharmaceutical Industries from $28.00 to $26.00 and set an "overweight" rating for the company in a report on Thursday, January 30th. UBS Group reduced their target price on Teva Pharmaceutical Industries from $30.00 to $27.00 and set a "buy" rating on the stock in a research note on Thursday, January 30th. Bank of America lowered their target price on shares of Teva Pharmaceutical Industries from $23.00 to $20.00 and set a "buy" rating for the company in a research note on Thursday, March 6th. Finally, Piper Sandler lifted their price objective on shares of Teva Pharmaceutical Industries from $23.00 to $30.00 and gave the company an "overweight" rating in a report on Friday, January 17th. One analyst has rated the stock with a hold rating and seven have assigned a buy rating to the company. According to MarketBeat.com, the stock currently has a consensus rating of "Moderate Buy" and a consensus price target of $23.43.

Teva Pharmaceutical Industries Stock Up 1.1 %

Shares of NYSE TEVA traded up $0.16 during mid-day trading on Friday, reaching $14.88. 6,566,648 shares of the company were exchanged, compared to its average volume of 9,929,030. Teva Pharmaceutical Industries Limited has a 1 year low of $12.47 and a 1 year high of $22.80. The firm has a 50-day moving average of $15.23 and a 200 day moving average of $17.56. The stock has a market cap of $16.87 billion, a price-to-earnings ratio of -10.26, a P/E/G ratio of 1.44 and a beta of 0.72. The company has a quick ratio of 0.75, a current ratio of 0.98 and a debt-to-equity ratio of 2.97.

Teva Pharmaceutical Industries (NYSE:TEVA - Get Free Report) last released its quarterly earnings results on Wednesday, January 29th. The company reported $0.70 EPS for the quarter, beating the consensus estimate of $0.69 by $0.01. Teva Pharmaceutical Industries had a negative net margin of 9.91% and a positive return on equity of 42.46%. On average, research analysts expect that Teva Pharmaceutical Industries Limited will post 2.5 earnings per share for the current year.

Teva Pharmaceutical Industries Company Profile

Teva Pharmaceutical Industries Limited develops, manufactures, markets, and distributes generic medicines, specialty medicines, and biopharmaceutical products in North America, Europe, Israel, and internationally. It offers generic medicines in various dosage forms, such as tablets, capsules, injectables, inhalants, liquids, transdermal patches, ointments, and creams; sterile products, hormones, high-potency drugs, and cytotoxic substances in parenteral and solid dosage forms; and generic products with medical devices and combination products.